Back to top
more

Orthofix Medical (OFIX)

(Delayed Data from NSDQ)

$18.40 USD

18.40
545,035

+0.69 (3.90%)

Updated Nov 6, 2024 03:59 PM ET

After-Market: $18.40 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Why You Should Add Hologic (HOLX) to Your Portfolio Now

by Zacks Equity Research

Hologic (HOLX) is currently well-positioned to achieve its full-year guidance of low double-digit organic growth ex-COVID in all three franchises, well above the 5-7% long-term growth rate.

Bruker Corporation (BRKR) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Bruker Corporation (BRKR) outperforms the industry and the S&P 500 due to impressive quarterly results and segmental prospects.

Orthofix (OFIX) Q4 Earnings Beat Estimates, Gross Margin Dips

by Zacks Equity Research

Orthofix (OFIX) reports impressive performance across the BGT and Global Orthopedics segment in the fourth quarter.

Orthofix (OFIX) Progresses With Limb-Lengthening Device

by Zacks Equity Research

Orthofix's (OFIX) Fitbone TAA intramedullary limb-lengthening system is implanted through a minimally invasive procedure.

Here's Why You Should Retain Boston Scientific (BSX) Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX) on recent acquisitions and robust performance of the WATCHMAN device.

Amedisys (AMED) Faces Macro Challenges, Margin Pressure

by Zacks Equity Research

The Contessa Health acquisition seems to be strategically aligned with Amedisys' (AMED) business.

Teleflex (TFX) OEM Arm Grows, Supply Issue Persists

by Zacks Equity Research

From a geographic perspective, Teleflex (TFX) is seeing strong results in Asia, which continues to be an important growth driver for Teleflex.

Here's Why Investors Should Retain Zimmer Biomet (ZBH) Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH) owing to ongoing business recovery from the COVID-led pandemic impact.

Globus Medical (GMED) Global Growth Strong Despite Margin Woe

by Zacks Equity Research

Despite continued margin declines in Japan, Globus Medical (GMED) remains positive on the progress and potential of its international business for long-term growth as it continues to reset the market in the country.

Syneos Health (SYNH) Hurt by Low Reimbursable Expense, FX Issue

by Zacks Equity Research

Syneos Health (SYNH) experiences delays in large pharma award decisions, with net awards being impacted by greater-than-normal delays.

Neogen (NEOG) Rises 7.9% Since Q1 Earnings: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Neogen's (NEOG) recent product launches and strong global presence.

Neogen (NEOG) Benefits From Advanced Portfolio, Global Growth

by Zacks Equity Research

Barring Australia and China, solid international operations also buoy optimism for Neogen (NEOG).

Here's Why You Should Retain Hologic (HOLX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Hologic (HOLX), led by the continued strength of the GYN Surgical business.

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Investors are optimistic about Charles River (CRL) on robust performances across the RMS and DSA segments.

Insulet's (PODD) Omnipod Sales Aid, Costs Continue to Rise

by Zacks Equity Research

Insulet (PODD) progresses well with respect to its four-pillar strategy, wherein the first two pillars include expanding access and awareness, and delivering consumer-focused innovation.

Abbott (ABT) to Upgrade PHCs Across India With New Pact

by Zacks Equity Research

Abbott's (ABT) HWC program is likely to benefit more than 2.5 million people from under-resourced communities annually.

Omnicell (OMCL) Ailed by Mounting Costs, Macroeconomic Issues

by Zacks Equity Research

Macroeconomic factors adversely affect bookings and revenues in Omnicell's (OMCL) point-of-care business. The company reduces its overall bookings and revenue outlook for the year.

SmileDirectClub (SDC) Gains From Innovation Amid Macro Issues

by Zacks Equity Research

A series of cutting-edge innovations, strategic distribution and insurance partnerships are added positives for SmileDirectClub (SDC).

Here's Why Investors Should Retain Thermo Fisher (TMO) Stock

by Zacks Equity Research

Investors are optimistic about Thermo Fisher's (TMO) continued strength across its certain end markets.

Here's Why You Should Retain Edwards Lifesciences (EW) Now

by Zacks Equity Research

Investors are optimistic about Edwards Lifesciences (EW), led by strong underlying growth across all product groups.

Bio-Rad (BIO) Core Diagnostic Sales Grow Amid Supply Challenges

by Zacks Equity Research

Bio-Rad's (BIO) underlying Life Science currency-neutral core revenue growth is primarily driven by Western loading, qPCR, process media and antibody products sales.

Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now

by Zacks Equity Research

Investors are optimistic about Quest Diagnostics (DGX) on strong growth in the base business.

Abbott's (ABT) FreeStyle Libre 3 Integrates With AID System

by Zacks Equity Research

Abbott's (ABT) FreeStyle Libre 3 integration with mylife Loop solutions will help build a smart, automated process to deliver insulin based on real-time glucose data.

Walgreens Boots (WBA) Gains From Digital Sales Amid Cost Woes

by Zacks Equity Research

Within the U.S. Healthcare segment, Walgreens Boots (WBA) is optimistic about the acquisition of CareCentrix.

Here's Why You Should Retain Boston Scientific (BSX) For Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX), led by new strategic investments and the robust performance of the WATCHMAN device.